- Home
- ITOS vs AUDC Comparison
ITOS vs AUDC Comparison
Compare ITOS & AUDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITOS
- AUDC
- Stock Information
- Founded
- ITOS 2011
- AUDC 1992
- Country
- ITOS United States
- AUDC Israel
- Employees
- ITOS N/A
- AUDC N/A
- Industry
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- AUDC Telecommunications Equipment
- Sector
- ITOS Health Care
- AUDC Utilities
- Exchange
- ITOS Nasdaq
- AUDC Nasdaq
- Market Cap
- ITOS 270.7M
- AUDC N/A
- IPO Year
- ITOS 2020
- AUDC 1999
- Fundamental
- Price
- ITOS $7.35
- AUDC $9.46
- Analyst Decision
- ITOS Strong Buy
- AUDC Buy
- Analyst Count
- ITOS 3
- AUDC 2
- Target Price
- ITOS $26.00
- AUDC $11.25
- AVG Volume (30 Days)
- ITOS 489.4K
- AUDC 112.8K
- Earning Date
- ITOS 05-09-2025
- AUDC 05-06-2025
- Dividend Yield
- ITOS N/A
- AUDC 1.90%
- EPS Growth
- ITOS N/A
- AUDC 78.82
- EPS
- ITOS N/A
- AUDC 0.50
- Revenue
- ITOS $35,000,000.00
- AUDC $242,176,000.00
- Revenue This Year
- ITOS N/A
- AUDC $5.11
- Revenue Next Year
- ITOS $31.74
- AUDC $3.81
- P/E Ratio
- ITOS N/A
- AUDC $18.92
- Revenue Growth
- ITOS 177.89
- AUDC N/A
- 52 Week Low
- ITOS $4.80
- AUDC $7.70
- 52 Week High
- ITOS $18.75
- AUDC $12.72
- Technical
- Relative Strength Index (RSI)
- ITOS 62.54
- AUDC 51.62
- Support Level
- ITOS $7.01
- AUDC $8.86
- Resistance Level
- ITOS $7.56
- AUDC $9.73
- Average True Range (ATR)
- ITOS 0.49
- AUDC 0.41
- MACD
- ITOS 0.26
- AUDC 0.13
- Stochastic Oscillator
- ITOS 92.39
- AUDC 83.64
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.